Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart, Inc. President and CEO Steven Lo reported a tax-related share disposition tied to restricted stock units (RSUs). On March 24, 2026, 126,028 shares of common stock were withheld by the company to satisfy income tax withholding and remittance obligations upon RSU vesting, rather than sold in the open market.
Following this withholding, Lo directly holds 2,485,606 shares of Vaxart common stock and indirectly holds 100,000 shares through the Lo Family Trust. The filing reflects routine equity compensation and associated tax treatment rather than a discretionary buy or sell decision.
Vaxart, Inc. SVP and Chief Scientific Officer Sean Tucker reported a tax-withholding share disposition related to vested RSUs. On March 24, 2026, 36,418 shares of common stock were withheld by the company at $0.694 per share to cover income tax obligations on RSUs that vested that day.
After this non-market, tax-related disposition, Tucker directly holds 886,735 shares. He also has indirect holdings of 51,465 shares in joint tenancy with Frances Chang and 9,060 shares held by his spouse, as reflected in the filing’s ownership entries.
Vaxart, Inc. reported an insider equity transaction by SVP and General Counsel Edward B. Berg related to tax withholding on vested stock awards. On March 18, 2026, 8,072 shares of common stock were disposed of at $0.6346 per share to satisfy income tax withholding obligations in connection with the net settlement of RSUs that vested on that date. This was not an open-market sale but a routine, issuer-withheld share disposition for taxes. Following the transaction, Berg directly held 791,786 common shares, which includes 70,781 shares acquired under Vaxart’s 2022 Employee Stock Purchase Plan.
Vaxart, Inc. Chief Medical Officer James F. Cummings reported a routine share withholding tied to restricted stock units. On March 18, 2026, 6,772 shares of common stock were withheld at $0.6346 per share to cover income tax obligations for vested RSUs. After this tax-withholding disposition, he directly holds 958,020 shares of Vaxart common stock, which includes 75,618 shares acquired under the 2022 Employee Stock Purchase Plan.
Vaxart, Inc. President and CEO Steven Lo reported a tax-related share disposition tied to RSU vesting. On March 18, 2026, 22,425 shares of common stock were withheld by the company at $0.6346 per share to cover income tax obligations on vested RSUs, a non-market transaction coded as "F." After this withholding, Lo directly owned 2,611,634 common shares and indirectly held 100,000 additional shares through the Lo Family Trust, indicating that his overall equity stake remains substantial despite the routine tax withholding.
Vaxart, Inc. senior executive Sean Tucker reported a routine tax-related share disposition tied to restricted stock unit vesting. On March 18, 2026, 8,072 shares of common stock were withheld by the company to cover income tax obligations from RSUs that vested on that date, a non-market transaction rather than an open-market sale. After this withholding, Tucker directly holds 923,153 common shares and has additional indirect holdings of 51,465 shares in joint tenancy with Frances Chang and 9,060 shares held by his spouse.
Vaxart, Inc. director and CEO Steven Lo received new equity awards as part of his compensation. He was granted stock options for 1,543,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. These options vest 25% on March 16, 2027 and then in 36 equal monthly installments until fully vested on March 16, 2030.
Lo also received a grant of 846,500 shares of common stock upon vesting of restricted stock units. Those units vest 25% on each anniversary of the vesting commencement date of March 16, 2026, fully vesting on the fourth anniversary. Following these awards, he directly holds 2,634,059 common shares and 1,543,000 options, plus an indirect holding of 100,000 shares through the Lo Family Trust.
Vaxart, Inc. SVP and Chief Scientific Officer Sean Tucker reported equity awards rather than open-market trades. He received a stock option covering 410,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments until March 16, 2030.
He also acquired 200,000 shares of common stock at no cash cost in connection with restricted stock units, which are scheduled to vest 25% on each anniversary of the March 16, 2026 vesting commencement date until the fourth anniversary. Following these awards, he directly holds 931,225 common shares, with additional indirect holdings of 51,465 shares in joint tenancy and 9,060 shares held by his spouse.
Vaxart, Inc.’s Chief Financial Officer, Jeroen Nicolaas Grasman, reported equity compensation grants. He was awarded 227,000 shares of Common Stock upon vesting of restricted stock units, bringing his direct Common Stock holdings to 577,000 shares.
He also received a stock option covering 455,000 shares of Common Stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The restricted stock units vest 25% on March 16, 2026 and then annually so they are fully vested on the fourth anniversary, while the option vests 25% on March 16, 2027 and then in 36 equal monthly installments until fully vested on March 16, 2030. These are compensation-related awards rather than open-market purchases.
Vaxart, Inc. reported that Chief Medical Officer James F. Cummings received new equity awards on March 16, 2026. He was granted stock options for 455,000 shares of common stock at an exercise price of $0.6795 per share, expiring on March 16, 2036. The option vests 25% on March 16, 2027 and then in 36 equal monthly installments until March 16, 2030. He also received 227,000 shares of common stock through vesting of restricted stock units, which vest 25% on each anniversary of March 16, 2026 over four years. Following these grants, he holds 964,792 shares of common stock directly.